No abstract available.
Budesonide* ; Humans

No abstract available.
Beclomethasone* ; Budesonide* ; Hydrocortisone*

PURPOSE: Cough-variant asthma (CVA) is a common cause of chronic cough in young children. Some children who have CVA eventually develop classic asthma. We evaluated the effect of inhaled corticosteroid and leukotriene receptor antagonist in young children who are suspected of having CVA. METHODS: Thirty-seven cough-variant asthma patients younger than 5-years-old were enrolled in this study. Fifteen were treated with pulmicort nebulization (500 micorgram, bid) for 4 weeks (Group A). Fourteen were treated with leukotriene receptor antagonist (Singulair, 4 mg) for 4 weeks (Group B). Eleven were treated with intermittent short-acting beta2-agonist nebulization (Group C). We evaluated the mean change of symptom score in night cough and sleep disturbance. RESULTS: There were no differences in age, sex, total IgE, total eosinophil count or duration of cough among the three groups. Group A and B showed significant improvement of night cough and sleep disturbance after treatment. (P< 0.05) In Group A and B, night cough was significantly improved after treatment more than in control. (P< 0.05) But improvements in sleep disturbance didn't have any signigicant differences between the three groups. (P= 1.0) CONCLUSION: Inhaled corticosteroid and leukotriene receptor antagonist are effective to control chronic cough in CVA children younger than 5-years-old.
Asthma* ; Budesonide ; Child ; Cough ; Eosinophils ; Humans ; Immunoglobulin E ; Receptors, Leukotriene*

The aims of this study are to compare the efficacy and side effects of intranasal budesonide as a dry powder and as a freonpropelled pressurized aerosol in the treatment of perennial allergic rhinitis and to assess the difference in compliance with the powder and aerosol. The study design was a randomized, double-blind crossover between two treatment groups over a six-week period. Twelve patients with symptomatic perennial allergic rhinitis received 400 microgram of intranasal budesonide administered daily as two puffs/nostril/day of the drug delivered by a freon-propelled aerosol for the first three weeks and as one inhalation/nostril/day of the pure drug powder for the next three weeks. Fourteen adults with allergic rhinitis received the drug in the reverse sequence. Patients recorded daily symptoms on diaries, and, at each clinic visit, adverse effects were recorded. Compliance with the powder and with the aerosol was also evaluated. During the six weeks, there were significant improvements in symptoms in both treatment groups, and the differences in efficacy and compliance with the medication between the two groups were not significant. Adverse effects included headaches, epistaxis, and nasal dryness ; however, they were not serious and equally distributed in the two groups. We conclude that powder and aerosolized budesonide improve the symptoms of perennial allergic rhinitis significantly with little difference in efficacy, side effects, and preference.
Adult ; Ambulatory Care ; Budesonide* ; Compliance ; Epistaxis ; Headache ; Humans ; Rhinitis*

The aims of this study are to compare the efficacy and side effects of intranasal budesonide as a dry powder and as a freonpropelled pressurized aerosol in the treatment of perennial allergic rhinitis and to assess the difference in compliance with the powder and aerosol. The study design was a randomized, double-blind crossover between two treatment groups over a six-week period. Twelve patients with symptomatic perennial allergic rhinitis received 400 microgram of intranasal budesonide administered daily as two puffs/nostril/day of the drug delivered by a freon-propelled aerosol for the first three weeks and as one inhalation/nostril/day of the pure drug powder for the next three weeks. Fourteen adults with allergic rhinitis received the drug in the reverse sequence. Patients recorded daily symptoms on diaries, and, at each clinic visit, adverse effects were recorded. Compliance with the powder and with the aerosol was also evaluated. During the six weeks, there were significant improvements in symptoms in both treatment groups, and the differences in efficacy and compliance with the medication between the two groups were not significant. Adverse effects included headaches, epistaxis, and nasal dryness ; however, they were not serious and equally distributed in the two groups. We conclude that powder and aerosolized budesonide improve the symptoms of perennial allergic rhinitis significantly with little difference in efficacy, side effects, and preference.
Adult ; Ambulatory Care ; Budesonide* ; Compliance ; Epistaxis ; Headache ; Humans ; Rhinitis*

PURPOSE: To evaluate the effect f nebulized budensonide and intramuscular dexamethasone in relieving laryngeal obstruction of croup. METHODS: Forty patients with moderate croup (croup scores of 3 to 7 out of 17) were randomly assigned to budesonide group [1 mg(2 ml) of nebulized budesonide, N=15], dexamethasone group [intramuscular dexamethasone(0.5 mg/kg) and nebulized saline, N=10] and control group(2 ml of nebulized saline, N=15). The changes of croup scores, heart rate, respiratory rate, and arterial oxygen saturation(SaO2) were observed at post-treatment of 2, 24, 36 and 48 hours. The duration of admission and the rates of improvement to the croup score of < or = 1 at the post-treatments were compared. RESULTS: Croup scores at 12, 24 and 36 hours post treatments were 1.7+/-0.8, 1.1+/-0.7 and 0.8+/-0.7 in budensonide group and 2.2+/-0.7, 1.2+/-0.8 and 1.0+/-0.5 in dexamethasone group respectively, which were significantly lower rate, and SaO2 were not significantly different among the three groups. Improved rates to croup score of <1 in budesonide group at post-treatments of 12, 24, and 36 jpirs were 53%, 73% and 87%, which were significantly higher than 0%, 13%, and 47% in control group (p<0.05). Improved rate to croup score of < or = 1 in dexamethasone group was 60^ which was significantly hgier than 13% in control group only at post-treatment of 24 hours (p<0.05). CONCLUSION: Nebulized budesonide and intramusculan dexamethasone are both effective in reducing obstructive symptoms in patients with moderate croup. The effect of nebulized budesonide was more rapid than that of intramuscular dexamethasone.
Budesonide* ; Croup ; Dexamethasone* ; Heart Rate ; Humans ; Oxygen ; Respiratory Rate

PURPOSE: Dexamethasone intramuscular injection and oral prednisolone have been known to be effective in the treatment of croup. The aim of this study was to determine whether nebulized budesonide leads to clinically important improvement in respiratory symptoms within four hours for child with mild to moderate croup. METHODS: Patients with croup visited to the department of Pediatrics, Han Il General Hospital from March 1995 to June 1996 were enrolled in this study. Patients were eligible if their age was between six months and six years, their total croup score was higher than 2 after breathing humidified air for at least 15 minutes. 28 patients were treated with 2mg (8ml) of nebulized budesonide and 8 patients with 8ml of normal saline as control group over the 30 minutes. Croup score, heart rate and respiratory rate were then assessed hourly for up to four hours. Side effects were also observed. RESULTS: 1) The croup score was improved from 3.6+/-0.8 to 1.9+/-0.9 at 4 hours after the nebulized budesonide treatment. 2) No significant differences in changes in heart rate were observed until 4 hours after both the nebulized budesonide group and control group. 3) Significant decrease in respiratory rate was observed at 4 hours after the nebulized budesonide group. 4) No specific side effects were noted during and 4 hours after the nebulized budesonide treatment. CONCLUSIONS: We concluded that nebulized budesonide leads to a prompt and important clinical improvement in children with mild to moderate croup without any specific side effects.
Budesonide* ; Child ; Croup* ; Dexamethasone ; Heart Rate ; Hospitals, General ; Humans ; Injections, Intramuscular ; Pediatrics ; Prednisolone ; Respiration ; Respiratory Rate

The egg is one of the most common food allergens, and immunologic reactivity to egg antigens may be an early marker of atopic disorders. Budesonide is a synthetic non-halogenated corticosteroid with 16 , 17 -butylidene dioxy portion, and it is one of the common causes of corticosteroid allergy together with tixocortol pivalate and hydrocortisone butyrate. The patient was a 12 year old female. She had developed atopic dermatitis mainly on the face since she was 1 year old. She applied budesonide cream for treating atopic dermatitis in our dermatologic clinic, but her facial lesion was aggravated. On past medical history, she had been suffered from an egg allergy since 1-year-old, and she was accidentally exposed to egg and developed large pruritic erythematous patch on entire body. This case could be considered as atopic dermatitis with egg and budesonide hypersensitivity on the basis of the clinical features and prick test, MAST, open food challenge and patch test.
Allergens ; Budesonide* ; Butyrates ; Child ; Dermatitis, Atopic* ; Egg Hypersensitivity ; Female ; Humans ; Hydrocortisone ; Hypersensitivity* ; Ovum* ; Patch Tests

The tools for asthma control assessment recommended by the current guideline are cognitive function- and effort-dependent, which is substantially impaired in the elderly. The aim of this study is to investigate objective assessment tools of asthma control status and previous asthma exacerbation (AE) in elderly subjects. Asthmatics aged >60 years who were treated with step 2 or 3 by the Global Initiative for Asthma (GINA) guideline were enrolled. During the 12-week study period, the subjects used either 400 µg of budesonide plus 10 mg of montelukast or 800 µg of inhaled budesonide. The occurrence of AE during the 4-week run-in and 12-week treatment period was monitored. After 12-week of treatment, sputum eosinophil count, peripheral eosinophil count, the plasma leukotriene E₄ (LTE₄), and prostaglandin F₂α (PGF₂α) metabolite levels were measured using the UHPLC/Q-ToF MS system. The study subjects were divided into group 1 (asthmatics who experienced AE during the study period) and group 2 (those who did not). A total of 101 patients aged 60-85 years were enrolled. Twenty-three patients (22.8%) had experienced AE. The plasma LTE₄ level, LTE₄/PGF₂α ratio, and peripheral eosinophil count were significantly higher in group 1 than in group 2 (P=0.023, P=0.010, P=0.033, respectively). The plasma LTE₄/PGF₂α ratio and peripheral eosinophil count at week 12 were significantly associated with previous AE (odds ratio [OR]=1.748, P=0.013; OR=1.256, P=0.027). Receiver operating characteristic (ROC) curves to discriminate the subjects with previous AE, including these 2 parameters, showed that the area under the curve was 0.700 (P=0.004), with 73.9% sensitivity and 47.9% specificity. In conclusion, a combination of plasma LTE₄/PGF₂α ratio and peripheral eosinophil count can be an objective assessment tool which is significantly associated with asthma control status in elderly asthmatics.
Aged* ; Asthma* ; Budesonide ; Eosinophils* ; Humans ; Plasma* ; ROC Curve ; Sensitivity and Specificity ; Sputum

BACKGROUND: Eosinophilia in the nasal secretion and mucosal tissues is the characteristic finding of allergic rhinitis. We compared the effects of nasal budesonide dipropionate and oral terfenadine on the symptom score and nasal secretion eosinophils in perennial allergic rhinitics. MATERIALS AND METHOD: Study subjects consisted of 81 patients with perennial allergic rhinitis and nasal eosinophilia. Fifty-seven patients were treated with nasal budesonide and 24 patients were treated with oral terfenadine for two weeks respectively. Nasal secretion eosinophils were measured as the percentage of total leukocytes under microscope. Symptom scores for sneezing, rhinorrhea, obstruction and itching were graded from 0 (no symptom) to 3 (severe symptom). RESULTS: In budesonide treatment group, symptom score reduction (total symptom score before treatment-total symptom score after treatment) was 5.1, while it was 2.3 in the terfenadine treatment group, which revealed a statistically significant difference (p<0.01). Reduction of eosinophils was 50% in the budesonide treatment group and 28% in terfenadine treatment group (p=0.045). There was statistically significant correlation between total symptom score and % eosinophils (r= 0.668 , p<0.01 ) CONCLUSION: Although both the nasal budesonide and oral terfenadine substantially reduced the proportion of eosinophils in the nasal secretion as well as symptoms in allergic rhinitics with eosinophilia, budesonide was superior to terfendine. Nasal eosinophils correlated with reduction of allergic symptoms in a statisticaly significant manner.
Budesonide* ; Eosinophilia ; Eosinophils* ; Humans ; Leukocytes ; Mucous Membrane ; Pruritus ; Rhinitis ; Sneezing ; Terfenadine*